The Food and Drug Administration’s recent approval of new Alzheimer’s drugs sparked a flicker of hope for the millions affected by this devastating disease. But this progress casts a puzzling shadow.
The drugs come at a high cost for relatively limited benefits, offering only a brief respite in the pace of cognitive decline. This reality raises a question: Are we fixated on such marginally effective treatments at the expense of more promising preventive measures?
Let's start with the truth!
Support the Broken Science Initiative.
Subscribe today →
recent posts
BSI Is excited to release our Investigation section of the Broken Science web site. This page features investigative work we've been doing in the background.
All of statistics and much of science depends on probability — an astonishing achievement, considering no one’s really sure what it is.
